HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

KROS

Keros Therapeutics Inc

Last Close
Oct 31  •  04:00PM ET
15.22
Dollar change
+0.19
Percentage change
1.26 %
Healthcare • Biotechnology • USA • NASD
Peers: SRPT VRTX ALNY IONS ARWR TVRD BLUE RGNX MCRB PBYI
 | Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO VHT LABU
IndexRUT P/E48.58 EPS (ttm)0.31 Insider Own6.77% Shs Outstand40.62M Perf Week1.20%
Market Cap463.69M Forward P/E- EPS next Y-4.39 Insider Trans-83.15% Shs Float28.40M Perf Month-2.31%
Enterprise Value-208.58M PEG31.34 EPS next Q-1.05 Inst Own103.29% Short Float13.44% Perf Quarter4.10%
Income18.77M P/S1.99 EPS this Y111.68% Inst Trans-27.66% Short Ratio6.01 Perf Half Y3.89%
Sales232.84M P/B0.87 EPS next Y-851.96% ROA3.10% Short Interest3.82M Perf YTD-3.85%
Book/sh17.40 P/C0.67 EPS next 5Y1.55% ROE3.33% 52W High72.37 -78.97% Perf Year-74.69%
Cash/sh22.66 P/FCF8.74 EPS past 3/5Y-25.74% -48.13% ROIC2.60% 52W Low9.12 66.89% Perf 3Y-67.48%
Dividend Est.- EV/EBITDA-124.90 Sales past 3/5Y-43.89% -18.71% Gross Margin99.42% Volatility3.34% 4.61% Perf 5Y-71.88%
Dividend TTM- EV/Sales-0.90 EPS Y/Y TTM106.91% Oper. Margin0.13% ATR (14)0.62 Perf 10Y-
Dividend Ex-Date- Quick Ratio21.11 Sales Y/Y TTM85820.30% Profit Margin8.06% RSI (14)50.11 Recom1.80
Dividend Gr. 3/5Y- - Current Ratio21.11 EPS Q/Q39.71% SMA200.24% Beta1.13 Target Price23.00
Payout- Debt/Eq0.03 Sales Q/Q49002.70% SMA50-1.44% Rel Volume1.05 Prev Close15.03
Employees169 LT Debt/Eq0.02 EarningsAug 06 AMC SMA20012.70% Avg Volume635.76K Price15.22
IPOApr 08, 2020 Option/ShortYes / Yes EPS/Sales Surpr.31.52% 352.33% Trades Volume665,742 Change1.26%
Date Action Analyst Rating Change Price Target Change
Oct-20-25Initiated Wells Fargo Overweight $26
Jun-10-25Downgrade BofA Securities Buy → Neutral $18
Jan-21-25Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-17-25Downgrade Wedbush Outperform → Neutral $15
Dec-16-24Reiterated Oppenheimer Outperform $102 → $63
Dec-16-24Downgrade Guggenheim Buy → Neutral
Dec-13-24Reiterated H.C. Wainwright Buy $100 → $47
Dec-12-24Downgrade William Blair Outperform → Mkt Perform
Dec-12-24Downgrade TD Cowen Buy → Hold
Dec-12-24Downgrade BTIG Research Buy → Neutral
Show Previous Ratings
Oct-21-25 09:43AM
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?
(Zacks)
Oct-20-25 06:00AM
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares
(GlobeNewswire) +9.83%
Oct-15-25 06:30AM
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
(GlobeNewswire)
Sep-08-25 08:00AM
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting
(GlobeNewswire)
Aug-28-25 04:01PM
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
(GlobeNewswire)
08:30AM Loading…
Aug-21-25 08:30AM
ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment
(PR Newswire) +6.61%
06:56AM
Keros gains FDA orphan drug status for DMD treatment KER-065
(Pharmaceutical Technology)
Aug-20-25 09:48AM
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
(GlobeNewswire)
Aug-06-25 05:45PM
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
(Zacks) -7.29%
04:15PM
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
(GlobeNewswire)
04:01PM
Keros Therapeutics Reports Second Quarter 2025 Financial Results
(GlobeNewswire)
Jul-28-25 11:40AM
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
(Zacks)
Jul-23-25 10:54AM
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
(Zacks) +5.10%
Jul-18-25 11:28AM
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
(Zacks)
10:39AM
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
(Zacks)
08:00AM Loading…
Jul-17-25 08:00AM
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
(GlobeNewswire)
Jul-10-25 12:10PM
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
(Zacks)
11:09AM
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
(Zacks)
Jun-11-25 09:40AM
McDonalds downgraded on GLP-1 drug worries: Wall Streets top analyst calls
(TipRanks)
Jun-10-25 02:37PM
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
(Benzinga)
Jun-09-25 03:12PM
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
(PR Newswire) -6.32%
06:55AM
Keros Announces Return of $375 Million in Excess Capital to Stockholders
(GlobeNewswire)
Jun-06-25 04:01PM
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference
(GlobeNewswire)
May-30-25 06:36AM
Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC
(BioPharma Dive)
May-29-25 11:24PM
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial
(Insider Monkey)
12:54PM
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
(Benzinga)
06:55AM
Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring
(GlobeNewswire)
May-27-25 01:45PM
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees
(GlobeNewswire)
May-21-25 08:00AM
ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth
(PR Newswire)
May-19-25 08:00AM
Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value
(GlobeNewswire)
12:11PM Loading…
May-12-25 12:11PM
ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth
(PR Newswire)
08:00AM
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
(GlobeNewswire)
May-08-25 05:31PM
Keros Reinforces Commitment to Maximizing Stockholder Value
(GlobeNewswire)
02:10PM
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders
(PR Newswire)
May-06-25 07:10PM
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates
(Zacks) -5.46%
04:01PM
Keros Therapeutics Reports Recent First Quarter 2025 Financial Results
(GlobeNewswire)
May-05-25 05:10PM
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
May-02-25 08:40AM
Implied Volatility Surging for Keros Therapeutics Stock Options
(Zacks)
Apr-11-25 02:13PM
Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation
(Seeking Alpha)
12:05PM
Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz
(TipRanks)
11:57AM
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
(Zacks)
Apr-10-25 12:58PM
Keros Therapeutics considers sale amid investor pressure
(Pharmaceutical Technology) +18.49%
06:00AM
Keros Therapeutics Announces Review of Strategic Alternatives
(GlobeNewswire)
Mar-31-25 06:00AM
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
(GlobeNewswire) -5.56%
Mar-21-25 09:55AM
Wall Street Analysts Think Keros Therapeutics (KROS) Could Surge 156.99%: Read This Before Placing a Bet
(Zacks)
Mar-05-25 09:55AM
Wall Street Analysts Believe Keros Therapeutics (KROS) Could Rally 153.67%: Here's is How to Trade
(Zacks)
Feb-28-25 05:00PM
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
(GlobeNewswire)
Feb-26-25 05:10PM
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
(Zacks)
04:01PM
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
(GlobeNewswire)
Jan-30-25 08:00AM
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
(GlobeNewswire)
Jan-22-25 08:53AM
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
(Zacks)
Jan-21-25 08:00AM
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept
(GlobeNewswire) +5.06%
Jan-20-25 09:35AM
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround
(Zacks)
Jan-16-25 09:35AM
Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 Weeks
(Zacks)
Jan-15-25 06:30AM
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial
(GlobeNewswire) -16.51%
Dec-14-24 06:50AM
Keros Therapeutics price target raised to $28 from $11 at Wells Fargo
(TipRanks)
Dec-12-24 04:11PM
Keros Plummets 73% After Unexpected Side Effects 'Shock' Its Lead Drug
(Investor's Business Daily) -73.15%
09:15AM
Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study
(Investor's Business Daily)
06:02AM
Keros shares collapse on unanticipated setback for lung disease drug
(BioPharma Dive)
06:00AM
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
(GlobeNewswire)
Dec-09-24 07:30PM
Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
(GlobeNewswire)
Dec-04-24 04:31AM
Takeda licensed for anaemia therapy by Keros Therapeutics
(Pharmaceutical Technology) +8.85%
Dec-03-24 12:37PM
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
(Benzinga) +9.78%
07:00AM
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
(Business Wire)
07:00AM
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept
(GlobeNewswire)
Nov-26-24 08:00AM
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
(GlobeNewswire)
Nov-06-24 04:01PM
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
(GlobeNewswire) +6.18%
08:00AM
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
(GlobeNewswire)
Nov-05-24 09:00AM
Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
(GlobeNewswire)
Oct-16-24 08:00AM
Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer
(GlobeNewswire)
Sep-12-24 08:00AM
Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare Conference
(GlobeNewswire)
Sep-05-24 03:24PM
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
(Investor's Business Daily)
Sep-03-24 08:00AM
Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS Trial
(GlobeNewswire) +5.38%
Aug-28-24 08:00AM
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
(GlobeNewswire)
Aug-07-24 11:53PM
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
(InvestorPlace) -6.89%
04:01PM
Keros Therapeutics Reports Second Quarter 2024 Financial Results
(GlobeNewswire)
Jun-17-24 04:01PM
Keros Therapeutics Announces Leadership Updates
(GlobeNewswire) -9.68%
06:00AM
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
(GlobeNewswire)
Jun-04-24 08:00AM
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
(GlobeNewswire)
Jun-03-24 08:00AM
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
(GlobeNewswire)
May-28-24 04:01PM
Keros Therapeutics Appoints Jean-Jacques Bienaime to its Board of Directors
(GlobeNewswire)
04:01PM
Keros Therapeutics Appoints Jean-Jacques Bienaim to its Board of Directors
(GlobeNewswire)
May-14-24 10:00AM
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
(GlobeNewswire)
May-10-24 01:25PM
Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
(GuruFocus.com) -5.78%
May-08-24 12:54PM
KROS Stock Earnings: Keros Therapeutics Beats EPS for Q1 2024
(InvestorPlace)
08:00AM
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
(GlobeNewswire)
Mar-14-24 08:00AM
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
(GlobeNewswire)
Mar-05-24 08:00AM
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
(GlobeNewswire)
Feb-28-24 04:42PM
Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023
(GuruFocus.com)
04:01PM
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
08:50AM
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
(Zacks)
Feb-21-24 09:55AM
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
(Zacks)
Feb-12-24 08:50AM
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
(Zacks) +7.02%
Jan-31-24 09:55AM
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
(Zacks)
Jan-29-24 08:00AM
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
(GlobeNewswire)
Jan-24-24 08:50AM
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
(Zacks)
Jan-23-24 09:55AM
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?
(Zacks)
Jan-15-24 09:55AM
How Much Upside is Left in Keros Therapeutics, Inc. (KROS)? Wall Street Analysts Think 57.46%
(Zacks)
Jan-09-24 08:00AM
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
(GlobeNewswire)
Jan-03-24 09:29PM
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
(GlobeNewswire) +18.47%
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pontifax Management 4 G.P. (2010% OwnerOct 15 '25Sale17.754,787,33184,975,1250Oct 17 05:53 PM
ADAR1 Capital Management, LLC10% OwnerOct 15 '25Sale17.755,389,26495,659,4360Oct 15 01:24 PM
Rovaldi ChristopherAffiliateSep 12 '25Proposed Sale15.7185,3061,340,157Sep 12 04:45 PM
ADAR1 Capital Management, LLC10% OwnerApr 09 '25Buy10.13934,2589,464,5124,392,737Apr 11 09:57 PM
Seehra JasbirCHIEF EXECUTIVE OFFICERApr 04 '25Option Exercise0.3049,36714,810302,223Apr 07 04:15 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

LBRX

LB Pharmaceuticals Inc

Last Close
Oct 31  •  04:00PM ET
16.13
Dollar change
-0.15
Percentage change
-0.92 %
Healthcare • Biotechnology • USA • NASD
LBRX LB Pharmaceuticals Inc daily Stock Chart
Held by: BMED
Index- P/E- EPS (ttm)- Insider Own20.79% Shs Outstand22.44M Perf Week1.00%
Market Cap361.96M Forward P/E- EPS next Y- Insider Trans107.17% Shs Float17.78M Perf Month4.33%
Enterprise Value- PEG- EPS next Q-0.57 Inst Own31.15% Short Float1.55% Perf Quarter-
Income- P/S- EPS this Y- Inst Trans20.58% Short Ratio0.99 Perf Half Y-
Sales- P/B- EPS next Y- ROA- Short Interest0.28M Perf YTD-6.76%
Book/sh- P/C- EPS next 5Y- ROE- 52W High20.25 -20.35% Perf Year-
Cash/sh- P/FCF- EPS past 3/5Y-109.72% - ROIC- 52W Low13.36 20.73% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.80% 7.65% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM- Oper. Margin- ATR (14)1.30 Perf 10Y-
Dividend Ex-Date- Quick Ratio- Sales Y/Y TTM- Profit Margin- RSI (14)49.22 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio- EPS Q/Q- SMA201.34% Beta- Target Price46.33
Payout- Debt/Eq- Sales Q/Q- SMA501.72% Rel Volume0.18 Prev Close16.28
Employees- LT Debt/Eq- EarningsSep 03 SMA2001.72% Avg Volume278.23K Price16.13
IPOSep 11, 2025 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume51,311 Change-0.92%
Date Action Analyst Rating Change Price Target Change
Oct-06-25Initiated Stifel Buy $27
Oct-06-25Initiated Piper Sandler Overweight $78
Oct-06-25Initiated Leerink Partners Outperform $34
Oct-14-25 08:30AM
LB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs
(GlobeNewswire)
Oct-06-25 08:30AM
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms
(GlobeNewswire)
Sep-25-25 08:30AM
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
(GlobeNewswire)
Sep-12-25 04:27PM
Crunching the numbers on this week's IPO performances
(Yahoo Finance Video)
LB Pharmaceuticals, Inc. engages in the research and development of novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its product pipeline includes LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Deep Track Biotechnology Maste10% OwnerSep 12 '25Buy15.002,000,00030,000,0002,686,138Sep 16 06:09 PM
Deep Track Biotechnology Maste10% OwnerSep 12 '25Buy15.00666,6669,999,990666,666Sep 16 06:09 PM
Pontifax Management 4 G.P. (2010% OwnerSep 12 '25Buy15.001,000,00015,000,0001,411,681Sep 16 04:15 PM
Nussbaum RanDirectorSep 12 '25Buy15.001,000,00015,000,0001,411,681Sep 16 04:15 PM
Vida Ventures GP III, L.L.C.10% OwnerSep 12 '25Buy15.00333,3334,999,995880,214Sep 16 03:46 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.